70 expansion process for activated human t cells … · a chemically-defined, animal component-free...
TRANSCRIPT
A CHEMICALLY-DEFINED, ANIMAL COMPONENT-FREE EX VIVO
EXPANSION PROCESS FOR ACTIVATED HUMAN T CELLS Annie Ngo and Jessie H. –T. Ni, Ph.D. Irvine Scientific, R&D Department, Santa Ana, CA USA
© 2017 Irvine Scientific. All rights reserved. PRIME -XV is a registered trademark of Irvine Scientific Sales Company, Inc. All o ther trademarks are the property of their respective owners .
Introduction
Methods
Conclusion
Results
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Initial PBMC CDM XSFM 10%FBS+RPMI
0
10
20
30
40
50
60
70
T CellCDM, ACF
XSFM 1 2 3 Lot 1 Lot 2
91154 Xeno-Free Media 10% Serum
Fo
ld E
xp
an
sio
n
Isotype
A
B A
B C
0%10%20%30%40%50%60%70%80%90%
100%
Initial PBMC Expanded Tcells
ReactivatedT cells
0
10
20
30
40
50
60
70
80
90
100
0
1
2
3
4
5
6
7
8
Initial plating ofcryopreserved T cells
Reactivation of T cells7 day culture
Pe
rce
nt
Via
bil
ity
(%
)
Via
ble
Ce
ll D
en
sity
(x
10
^6
cell
s/w
ell
) VCD
% Viability
Reactivated T cells (7 days)
Isotype
Expanded T cells (14 days)
A B C
µ
CD3 + CD8+ CD3 + CD4+
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Initial PBMC PRIME-XV T CellCDM
T Cell XSFM
Pe
rce
nt
Exp
ress
ion
(%
)
CD3 + CD8+ CD3 + CD4+
CD3 + CD8+ CD3 + CD4+
CD3 + CD4+
CD3 + CD8+
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
Viab
le C
ell C
ount
(x10
6 cells
)
Treg:
CD4+/CD25+/FoxP3+
© 2017 Irvine Scientific. P/N 10704CT Rev. 0
0102030405060708090100
0102030405060708090
100
T Cell CDM,ACF
XSFM 1 2 3 Lot 1 Lot 2
91154 Xeno-Free Media 10% Serum
Pe
rce
nt
Via
bili
ty
CD
3+
Fold
Exp
ansi
on
Day 9 VCD
Isotype
XSFM
10%FBS+RPMI
CDM
0
50
100
150
200
250
Day 0 Day 5 Day 7 Day 9 Day 12 Day 14
CD3+
Fol
d Ex
pans
ion PRIME-XV T Cell CDM
T Cell XSFMPRIME-XV T Cell CDM Xeno-Free Medium
Day 9 Fold Expansion